Metabolic, endocrine and haemodynamic risk factors in the patient with peripheral arterial disease.

    Research output: Contribution to journalArticle

    12 Citations (Scopus)

    Abstract

    The morbidity and mortality associated with peripheral arterial disease (PAD) creates a huge burden in terms of costs both to the patient and to the health service. PAD is a deleterious and progressive condition that causes a marked increase in the risk of cardiovascular and cerebrovascular events. Further, PAD has a major negative impact on quality of life and mortality, and is associated with an increased risk of limb amputation. The clinical profile of patients at risk of PAD overlaps considerably with the known cardiovascular risk factors. These include, increasing age, smoking habit, diabetes, hypertension, dyslipidaemia, male sex and hyperhomocysteinaemia. For women, hormone replacement therapy appears to be associated with a reduced risk of PAD. Published PAD guidelines recommend aggressive management of risk factors, stressing the importance of lifestyle modification, antiplatelet agents, treating dyslipidaemia and diabetes. However, a large number of patients with PAD go undetected, either because they do not report their symptoms or because they are asymptomatic. It is therefore important to improve detection rates so that these patients can receive appropriate risk factor management.
    Original languageEnglish
    Pages (from-to)S7-S13
    Number of pages7
    JournalDiabetes, Obesity & Metabolism
    Volume4
    Issue numberS2
    DOIs
    Publication statusPublished - Mar 2002

    Fingerprint

    Peripheral Arterial Disease
    Hemodynamics
    Dyslipidemias
    Hyperhomocysteinemia
    Mortality
    Platelet Aggregation Inhibitors
    Hormone Replacement Therapy
    Risk Management
    Amputation
    Habits
    Health Services
    Life Style
    Extremities
    Smoking
    Quality of Life
    Guidelines
    Hypertension
    Morbidity
    Costs and Cost Analysis

    Cite this

    @article{5666a024d405434fadf7da3c43c81174,
    title = "Metabolic, endocrine and haemodynamic risk factors in the patient with peripheral arterial disease.",
    abstract = "The morbidity and mortality associated with peripheral arterial disease (PAD) creates a huge burden in terms of costs both to the patient and to the health service. PAD is a deleterious and progressive condition that causes a marked increase in the risk of cardiovascular and cerebrovascular events. Further, PAD has a major negative impact on quality of life and mortality, and is associated with an increased risk of limb amputation. The clinical profile of patients at risk of PAD overlaps considerably with the known cardiovascular risk factors. These include, increasing age, smoking habit, diabetes, hypertension, dyslipidaemia, male sex and hyperhomocysteinaemia. For women, hormone replacement therapy appears to be associated with a reduced risk of PAD. Published PAD guidelines recommend aggressive management of risk factors, stressing the importance of lifestyle modification, antiplatelet agents, treating dyslipidaemia and diabetes. However, a large number of patients with PAD go undetected, either because they do not report their symptoms or because they are asymptomatic. It is therefore important to improve detection rates so that these patients can receive appropriate risk factor management.",
    author = "Belch, {Jill J F}",
    year = "2002",
    month = "3",
    doi = "10.1046/j.1463-1326.2002.0040s20s7.x",
    language = "English",
    volume = "4",
    pages = "S7--S13",
    journal = "Diabetes, Obesity & Metabolism",
    issn = "1462-8902",
    publisher = "Wiley",
    number = "S2",

    }

    Metabolic, endocrine and haemodynamic risk factors in the patient with peripheral arterial disease. / Belch, Jill J F.

    In: Diabetes, Obesity & Metabolism, Vol. 4, No. S2, 03.2002, p. S7-S13.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Metabolic, endocrine and haemodynamic risk factors in the patient with peripheral arterial disease.

    AU - Belch, Jill J F

    PY - 2002/3

    Y1 - 2002/3

    N2 - The morbidity and mortality associated with peripheral arterial disease (PAD) creates a huge burden in terms of costs both to the patient and to the health service. PAD is a deleterious and progressive condition that causes a marked increase in the risk of cardiovascular and cerebrovascular events. Further, PAD has a major negative impact on quality of life and mortality, and is associated with an increased risk of limb amputation. The clinical profile of patients at risk of PAD overlaps considerably with the known cardiovascular risk factors. These include, increasing age, smoking habit, diabetes, hypertension, dyslipidaemia, male sex and hyperhomocysteinaemia. For women, hormone replacement therapy appears to be associated with a reduced risk of PAD. Published PAD guidelines recommend aggressive management of risk factors, stressing the importance of lifestyle modification, antiplatelet agents, treating dyslipidaemia and diabetes. However, a large number of patients with PAD go undetected, either because they do not report their symptoms or because they are asymptomatic. It is therefore important to improve detection rates so that these patients can receive appropriate risk factor management.

    AB - The morbidity and mortality associated with peripheral arterial disease (PAD) creates a huge burden in terms of costs both to the patient and to the health service. PAD is a deleterious and progressive condition that causes a marked increase in the risk of cardiovascular and cerebrovascular events. Further, PAD has a major negative impact on quality of life and mortality, and is associated with an increased risk of limb amputation. The clinical profile of patients at risk of PAD overlaps considerably with the known cardiovascular risk factors. These include, increasing age, smoking habit, diabetes, hypertension, dyslipidaemia, male sex and hyperhomocysteinaemia. For women, hormone replacement therapy appears to be associated with a reduced risk of PAD. Published PAD guidelines recommend aggressive management of risk factors, stressing the importance of lifestyle modification, antiplatelet agents, treating dyslipidaemia and diabetes. However, a large number of patients with PAD go undetected, either because they do not report their symptoms or because they are asymptomatic. It is therefore important to improve detection rates so that these patients can receive appropriate risk factor management.

    U2 - 10.1046/j.1463-1326.2002.0040s20s7.x

    DO - 10.1046/j.1463-1326.2002.0040s20s7.x

    M3 - Article

    VL - 4

    SP - S7-S13

    JO - Diabetes, Obesity & Metabolism

    JF - Diabetes, Obesity & Metabolism

    SN - 1462-8902

    IS - S2

    ER -